Ir a inicio
Muhammed Mustafa Atci
14
años de experiencia

Muhammed Mustafa Atci

  • Especialidad: Oncólogo clínico
  • 14 años de experiencia
  • Idiomas:
    Inglés, Turco
  • Consultas online: disponible
  • Consultorio: Turquía, Estambul, İstinye University Liv Hospital Topkapı
  • Miembro de la Sociedad Americana de Oncología Clínica (ASCO) desde 2018.

    El Dr. Muhammed Mustafa Atci es Profesor Asociado de Oncología Médica en İstinye University, Liv Hospital Topkapı (2025–presente). Anteriormente fue Profesor Asociado y Coordinador de Docencia en el Hospital de la Ciudad Prof. Dr. Cemil Taşcıoğlu (2023–2025). También fue oncólogo médico allí (2018–2021).

    Es miembro de ASCO y de la Sociedad Turca de Oncología Médica desde 2018. Es autor o coautor de 19 artículos internacionales revisados por pares sobre cáncer de colon, mama, estómago, páncreas, pulmón y tiroides, así como sobre sarcomas y cáncer colorrectal.

    Entre sus trabajos destacados figuran un estudio multicéntrico sobre la supervivencia en cáncer de colon en estadio IIB (Journal of Chemotherapy). También investigó el cociente de De Ritis para metástasis pulmonares en cáncer testicular (Current Urology). Sus estudios pronósticos utilizaron PET/TC, MSI, la relación ganglionar y el volumen tumoral metabólico.

Consulta médica online con Muhammed Mustafa Atci

Cómodo y sencillo
100% segura y confidencial
Precio a consultar

Servicios médicos

Ver más

¿Qué tal su experiencia?

1 de 3
La información sobre este doctor es completa y clara
1
2
3
4
5
Totalmente en desacuerdo
Totalmente de acuerdo

Formación académica

Education

Doctor of Medicine (M.D.)
2003 – 2009
Istanbul University – Cerrahpaşa Faculty of Medicine, Turkey

Residency in Internal Medicine
2011 – 2015
University of Health Sciences – Istanbul Şişli Hamidiye Etfal Health Application and Research Center, Department of Internal Medicine, Turkey

Professional Experience

Internal Medicine Specialist
2015 – 2017
Tokat State Hospital, Turkey

Internal Medicine Specialist
2017 – 2018
Istanbul Haseki Training and Research Hospital, Turkey

Medical Oncologist
2018 – 2021
University of Health Sciences – Istanbul Prof. Dr. Cemil Taşcıoğlu City Health Application and Research Center, Department of Internal Medicine / Oncology Department, Turkey

Associate Professor of Medical Oncology & Education Coordinator
2023 – 2025
Ministry of Health – Prof. Dr. Cemil Taşcıoğlu City Hospital, Turkey

Education Coordinator for the Medical Oncology Sub-Branch

Associate Professor of Medical Oncology
2025 – Present
İstinye University, Liv Hospital Topkapı, Turkey

Memberships to Scientific Organizations

American Society of Clinical Oncology (ASCO) – Member since 2018

Turkish Society of Medical Oncology – Member since 2018


Articles Published in Peer-Reviewed International Journals

1. Atcı, M. M., Akagündüz, B., Demir, M., Arıkan, R., Ay Ersoy, S., Özer, M., Ayhan, M., Çil, İ., Demir, N., Özyurt, N., Karakaya, G., Çevik, G. T., Önder, A. H., Selvi, O., Sakin, A. (2023). The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Journal of Chemotherapy.

2. Bozkurt, M., Aghalarov, S., Atcı, M. M., Selvi, O., Canat, H. L. (2022). A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio. Current Urology.

3. Dülgar, Ö., Öven, B. B., Atcı, M. M., Arıkan, R., Ay Ersoy, S., Ayhan, M., Selvi, O., Tataroğlu Özyükşeler, D., Bayram, E., Özcan, E., Yasin, A. İ., Gümüş, M. (2022). Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Review of Anticancer Therapy.

4. Akagündüz, B., Altın, Z., Atcı, M. M., Özer, M., Güven, D. C., Çil, İ., Özçiçek, F., Demirtaş, L., Düzgün, E., Gunderci, A., Arslan, Y. (2021). Assessment of abuse and related factors in older patients with cancer. Supportive Care in Cancer.

5. Akagündüz, B., Özer, M., Karaçin, C., Atcı, M. M., Yıldırım, H. Ç., Ünver, E. (2021). Impact of coronaphobia on treatment and follow-up compliance of cancer patients. Future Oncology.

6. Arıcı, S., Sağlampınar Karyağar, S., Uslu Erdemir, R., Çekin, R., Atcı, M. M., Güven, O., Karyağar, S., Cihan, Ş. (2021). The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in patients with advanced medullary thyroid cancer. Revista Española de Medicina Nuclear e Imagen Molecular.

7. Atcı, M. M., Gerede, Ç., Ay Ersoy, S., Ertürk, B., Seçmeler, Ş., Arıcı, S., Çekin, R., Yaşar, N., Can, O., Cihan, Ş., Gümüş, M. (2021). Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: A retrospective study. European Journal of Breast Health.

8. Calm, A., Atcı, M. M., Aldemir, M. N., Akagündüz, B., Şahin, S., Arıcı, S., Seçmeler, Ş., Cihan, Ş. (2021). The prognostic value of postoperative lymph node ratio in neoadjuvant-treated gastric adenocarcinoma patients. Cureus.

9. Calm, A., Şahin, S., Sağlampınar Karyağar, S., Karyağar, S., Atcı, M. M., Akbörü, M. H., Cihan, Ş. (2021). The predictive value of baseline volumetric PET/CT parameters on treatment response and prognosis in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Journal of Gastrointestinal Cancer.

10. Arıcı, S., Şengiz Erhan, S., Geredeli, Ç., Atcı, M. M., Seçmeler, Ş., Çekin, R., Sakin, A., Cihan, Ş. (2021). The prognostic importance of microsatellite instability status in Turkish stage II and III gastric cancer patients who received adjuvant chemotherapy. International Journal of Hematology and Oncology.

11. Calm, A., Şahin, S., Atcı, M. M., Ayşegül, P., Yaşar, N., Geredeli, Ç., Aksaray, F., Cihan, Ş. (2021). The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology.

12. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Geredeli, Ç., Cihan, Ş. (2021). Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer. Journal of Surgery and Medicine (JOSAM).

13. Akagündüz, B., Akın Telli, T., Yıldırım, H. Ç., Sezgin Göksu, S., Demir, N., Hafızoğlu, E., Özer, M., Çevik, G. T., Sakin, A., Göktaş, A. S., Şengül Samancı, N., Özyurt, N., Atcı, M. M., Ayhan, M., Turan, M., Sarıyar, N., Karaçin, C., Kılıçkap, S., Paydaş, S., Doğan, M. (2021). Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group. International Journal of Hematology and Oncology.

14. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Demir, C., Geredeli, Ç., Sakin, A., Cihan, Ş. (2020). The effect of body mass index on treatment outcomes in patients with metastatic non-small cell lung cancer treated with platinum-based therapy. Nutrition and Cancer.

15. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Yaşar, N., Arıcı, S., Geredeli, Ç., Karataş, F., Cihan, Ş. (2020). Assessment of pre-treatment albumin-bilirubin grade in pancreatic cancer patients with liver metastases. Journal of BUON.

16. Abdullah, P., Süleyman, Ş., Ayşegül, P., Atcı, M. M., Serdar, A., Yaşar, N., Demir, C., Geredeli, Ç., Cihan, Ş. (2020). Factors affecting survival in operated pancreatic cancer; Does tumor localization have a significant effect on treatment outcomes? Northern Clinics of Istanbu.

17. Arıcı, S., Sağlampınar Karyağar, S., Karyağar, S., Geredeli, Ç., Çekin, R., Seçmeler, Ş., Atcı, M. M., Sakin, A., Cihan, Ş. (2020). The predictive role of metabolic tumor volume on non-response to neoadjuvant chemotherapy in patients with breast cancer. Journal of Oncology Pharmacy Practice.

18. Calm, A., Yılmaz, Y., Şahin, S., Atcı, M. M., Arıcı, S., Geredeli, Ç., Yaşar, N., Demir, C., Cihan, Ş. (2020). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. Northern Clinics of Istanbul.

19. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Geredeli, Ç., Arıbal, S., Alemdar, A., Karataş, F., Cihan, Ş. (2019). Factors affecting survival in patients with isolated liver-metastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis. Journal of BUON.

También le puede interesar

Pagos y Beneficios

Nuestros servicios no tienen costo

El pago se realiza directamente en la clínica o mediante transferencia a su cuenta bancaria oficial.

Reserva segura

Algunas clínicas pueden requerir un depósito como parte de su política.

Pagos en cuotas flexibles

Pague cómodamente en cuotas flexibles.

Programa de referencias

Reciba recompensas por recomendar Bookimed a sus amigos.